Clinical practice. Prolactinoma.

[1]  P. Cappabianca,et al.  Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia , 2003 .

[2]  M. Bonati,et al.  Pregnancy outcome after cabergoline treatment in early weeks of gestation. , 2002, Reproductive toxicology.

[3]  A. Breier,et al.  The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. , 2000, Clinical therapeutics.

[4]  E. Russell,et al.  Current approaches to imaging of the sellar region and pituitary. , 1999, Endocrinology and metabolism clinics of North America.

[5]  W. Jeffcoate,et al.  Long‐term follow‐up of patients with hyperprolactinaemia , 1996, Clinical endocrinology.

[6]  L. Musatti,et al.  Pregnancy outcome after treatment with the ergot derivative, cabergoline. , 1996, Reproductive toxicology.

[7]  R. Comtois,et al.  High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas , 1996, Clinical endocrinology.

[8]  J. Webster,et al.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea , 1994, The New England journal of medicine.

[9]  M. Hull,et al.  The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. , 1992, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[10]  R. Croughs,et al.  Withdrawal of bromocriptine after long‐term therapy for macroprolactinomas; effect on plasma prolactin and tumour size , 1991 .

[11]  C. Flamigni,et al.  Vaginal bromocriptine in hyperprolactinemic patients and puerperal women , 1991, Acta obstetricia et gynecologica Scandinavica.

[12]  O. Kletzky,et al.  Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia , 1989 .

[13]  B. Sherman,et al.  The natural history of untreated hyperprolactinemia: a prospective analysis. , 1989, The Journal of clinical endocrinology and metabolism.

[14]  D. Schoenfeld,et al.  Effects of prolactin and estrogen deficiency in amenorrheic bone loss. , 1988, The Journal of clinical endocrinology and metabolism.

[15]  L. Wide,et al.  Prolactin secretion and menstrual function after long-term bromocriptine treatment. , 1987, Fertility and sterility.

[16]  M. Liu,et al.  LONG‐TERM TREATMENT OF HYPERPROLACTINAEMIA WITH BROMOCRIPTINE: EFFECT OF DRUG WITHDRAWAL , 1987, Clinical endocrinology.

[17]  M. Kathol,et al.  Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. , 1987, The Journal of clinical endocrinology and metabolism.

[18]  B. Sherman,et al.  Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. , 1986, The Journal of clinical endocrinology and metabolism.

[19]  A. Liuzzi,et al.  Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. , 1985, The New England journal of medicine.

[20]  M. Molitch.  Pregnancy and the hyperprolactinemic woman. , 1985, The New England journal of medicine.

[21]  M. Molitch,et al.  Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study* , 1985 .

[22]  P. Snyder,et al.  Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. , 1984, Annals of Internal Medicine.

[23]  T. Uozumi,et al.  Necrotic changes in prolactinomas after long term administration of bromocriptine. , 1984, The Journal of clinical endocrinology and metabolism.

[24]  D. Cook,et al.  EFFECT OF DOPAMINE AGONIST WITHDRAWAL AFTER LONG-TERM THERAPY IN PROLACTINOMAS Studies with High-definition Computerised Tomography , 1984, The Lancet.

[25]  J. Raymond,et al.  Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. , 1983, American journal of obstetrics and gynecology.

[26]  J. Hardy,et al.  Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. , 1983, The New England journal of medicine.

[27]  J. Rose,et al.  Hyperprolactinemia-galactorrhea induced by verapamil. , 1983, The American journal of cardiology.

[28]  G. Besser,et al.  PULSATILE GONADOTROPHIN SECRETION IN HYPERPROLACTINAEMIC AMENORRHOEA AND THE RESPONSE TO BROMOCRIPTINE THERAPY , 1982, Clinical endocrinology.

[29]  R. Gore-Langton,et al.  Prolactin inhibits oestrogen synthesis in the ovary , 1981, Nature.

[30]  B. Brown,et al.  Surgery during pregnancy and fetal outcome. , 1980, American journal of obstetrics and gynecology.

[31]  D. Granner,et al.  Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study. , 1980, Endocrine reviews.

[32]  L. Frohman,et al.  Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. , 1980, The Journal of clinical endocrinology and metabolism.

[33]  J. Carter,et al.  Prolactin-screening tumors and hypogonadism in 22 men. , 1978, The New England journal of medicine.

[34]  A. Breckenridge,et al.  Effects of methyldopa on prolactin and growth hormone. , 1976, British medical journal.

[35]  S. Lal,et al.  EFFECT OF ACUTE AND CHRONIC NEUROLEPTIC THERAPY ON SERUM PROLACTIN LEVELS IN MEN AND WOMEN OF DIFFERENT AGE GROUPS , 1976, Clinical endocrinology.

[36]  S. Yen,et al.  Augmentation of prolactin secretion by estrogen in hypogonadal women. , 1974, The Journal of clinical investigation.

[37]  W. Daughaday,et al.  Thyroid Hormone Inhibition of the Prolactin Response to Thyrotropin-Releasing Hormone , 1973 .

[38]  R. Urban,et al.  A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. , 1991, American journal of obstetrics and gynecology.

[39]  F. Naftolin,et al.  Breast examination does not elevate serum prolactin. , 1980, Fertility and sterility.